Genmab expands immunology reach in argenx pact

By Jonathan Smith

In a move to increase its presence in immunology and inflammation, the Danish biotech Genmab has launched a collaboration with argenx in the Netherlands to co-discover and co-develop antibody treatments.


Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.